Annovis Bio Inc (ANVS) Stock Price, Quote & News

Company Profile

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive ca...

Industry: Biotechnology

Sector: Healthcare

Phone: 484 875 3192

Website: www.annovisbio.com

Address:

101 Lindenwood Drive, Suite 225, Malvern, United States

ScottHopko Aug. 25 at 3:48 PM

$ANVS is brewing. $MRNA is up big today.

0 · Reply

FRF Aug. 25 at 3:06 PM

$ANVS

0 · Reply

NolAsrtormZ Aug. 25 at 2:33 PM

$ANVS institutions dont care how many shares Maria puts on the market 🤣 What if the offering is higher then current share value🤫🤫🤫

0 · Reply

NolAsrtormZ Aug. 25 at 2:23 PM

$ANVS they need zeeee, caszhh ;)

1 · Reply

NolAsrtormZ Aug. 25 at 2:03 PM

$ANVS Institutions could care less if Maria has to do another offering

1 · Reply

NolAsrtormZ Aug. 25 at 2:01 PM

$ANVS im gambling with the institutions at near, near All time Lows for a Phase 3 Alzheimers play

1 · Reply

NolAsrtormZ Aug. 25 at 2:00 PM

$ANVS Institutions Buying in Impatient retail selling. Its been A very long 5 years for this data. Institutions coukd care less if retail got burnt buying in the $90's, $80's, $70's, range, institutions could care less that Maria didn't do an offering in the $50.00 range.

0 · Reply

To_De_Moon Aug. 25 at 1:32 PM

$ANVS https://zoom.us/webinar/register/WN_QRF6xO03S9GwsDvpfsxsog#/registration

0 · Reply

ForestFoxes Aug. 25 at 1:13 PM

$ANVS 📉 Corporate Update Webinar: Wednesday, September 2, 2026 at 4:00 pm EDT … followed by a live Q&A session with 900% confidence that the drug works.

1 · Reply

NolAsrtormZ Aug. 25 at 12:16 PM

$ANVS Gained at least 375 watchers that SAY NOTHING since full enrollment So a few of us keep them informed

2 · Reply

Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results

Aug 14, 2026, 7:00 AM EDT - 11 days ago

Annovis Bio Earnings release: Q2 2026

Aug 14, 2026, 7:00 AM EDT - 11 days ago

Annovis Bio Quarterly report: Q2 2026

Aug 3, 2026, 9:00 AM EDT - 22 days ago

Annovis Bio Slides: Investor presentation

2026-07-07T20:16:13.000Z - 6 weeks ago

Annovis Bio initiated with a Buy at Roth Capital

2026-07-07T11:20:30.000Z - 7 weeks ago

Annovis Bio announces full enrollment for buntanetap trial

Jul 7, 2026, 7:00 AM EDT - 7 weeks ago

Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer's Disease

2026-07-01T12:05:20.000Z - 7 weeks ago

Annovis Bio promotes Cheng Fang to chief scientific officer

Jul 1, 2026, 8:00 AM EDT - 7 weeks ago

Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer

2026-05-26T15:07:38.000Z - 3 months ago

Annovis Bio regains NYSE listing compliance

May 26, 2026, 8:00 AM EDT - 3 months ago

Annovis Bio Regains NYSE Listing Compliance

2026-05-20T12:20:11.000Z - 3 months ago

Annovis Bio 7.9M share Spot Secondary priced at $1.90

May 20, 2026, 8:00 AM EDT - 3 months ago

Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants

2026-05-19T20:12:17.000Z - 3 months ago

Annovis Bio announces common stock and warrants offering, no amount given

May 19, 2026, 4:06 PM EDT - 3 months ago

Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants

May 15, 2026, 7:30 AM EDT - 3 months ago

Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results

May 15, 2026, 7:00 AM EDT - 3 months ago

Annovis Bio Quarterly report: Q1 2026

May 15, 2026, 7:00 AM EDT - 3 months ago

Annovis Bio Earnings release: Q1 2026

May 14, 2026, 7:00 AM EDT - 3 months ago

Annovis Bio Slides: Corporate presentation

May 7, 2026, 7:30 AM EDT - 3 months ago

Annovis CEO to Present on Multi-Protein Model of Alzheimer's Disease at Fierce Biotech Week 2026

Apr 30, 2026, 8:00 AM EDT - 4 months ago

Annovis Bio Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 4 months ago

Annovis Bio Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio

Apr 10, 2026, 8:30 AM EDT - 4 months ago

Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission

Apr 9, 2026, 8:30 AM EDT - 4 months ago

Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants

Apr 8, 2026, 7:00 AM EDT - 4 months ago

Annovis Bio Slides: Corporate presentation

2026-04-02T11:54:03.000Z - 5 months ago

Annovis Bio secures U.S. patent for buntanetap

Apr 2, 2026, 7:30 AM EDT - 5 months ago

Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections

Mar 31, 2026, 8:00 AM EDT - 5 months ago

Annovis Publishes Historical Review of Buntanetap in The Scientist

Mar 24, 2026, 7:00 AM EDT - 5 months ago

Annovis Bio Slides: Corporate presentation

2026-03-19T11:56:46.000Z - 5 months ago

Annovis Bio enters partnership with NeuroRPM

Mar 19, 2026, 7:30 AM EDT - 5 months ago

Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study

Mar 19, 2026, 7:30 AM EDT - 5 months ago

NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial

2026-03-16T11:41:50.000Z - 5 months ago

Annovis Bio sees cash runway to 3Q26

2026-03-16T11:35:20.000Z - 5 months ago

Annovis Bio reports FY25 EPS ($1.40) vs. ($2.31) last year

Mar 16, 2026, 7:30 AM EDT - 5 months ago

Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results

Mar 16, 2026, 7:00 AM EDT - 5 months ago

Annovis Bio Earnings release: Q4 2025

Mar 16, 2026, 7:00 AM EDT - 5 months ago

Annovis Bio Annual report: Q4 2025

Mar 3, 2026, 8:00 AM EST - 6 months ago

Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference

2026-02-12T13:21:18.000Z - 6 months ago

Annovis Bio secures DSMB approval to advance Phase 3 trial of buntanetap

Feb 12, 2026, 8:00 AM EST - 6 months ago

Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer's Disease

2025-12-18T21:40:13.000Z - 8 months ago

Annovis Bio reports open-label extension study for Parkinson’s disease patients

Dec 18, 2025, 4:35 PM EST - 8 months ago

Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients

Dec 16, 2025, 8:00 AM EST - 9 months ago

Annovis to Host Corporate Update Webinar on January 28, 2026

Dec 3, 2025, 8:00 AM EST - 9 months ago

Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group

Nov 24, 2025, 8:00 AM EST - 9 months ago

Annovis Announces Two Presentations at the CTAD 2025 Conference

2025-11-18T14:39:45.000Z - 10 months ago

Annovis announces FDA meeting to discuss PDD program

Nov 18, 2025, 8:00 AM EST - 10 months ago

Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study

2025-11-17T13:10:41.000Z - 10 months ago

Annovis Bio announces biomarker data on amyloid co-pathology in Parkinson’s

Nov 17, 2025, 8:00 AM EST - 10 months ago

Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients

2025-11-12T13:11:18.000Z - 10 months ago

Annovis Bio reports Q3 EPS (37c) vs. (97c) last year

2025-11-12T13:10:52.000Z - 10 months ago

Annovis Bio sees cash runway to 3Q26

Nov 12, 2025, 8:00 AM EST - 10 months ago

Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results

Nov 12, 2025, 7:00 AM EST - 10 months ago

Annovis Bio Earnings release: Q3 2025

Nov 12, 2025, 7:00 AM EST - 10 months ago

Annovis Bio Quarterly report: Q3 2025

2025-11-06T13:32:03.000Z - 10 months ago

Annovis Bio says all 84 sites fully activated for Phase 3 study in early AD

Nov 6, 2025, 8:00 AM EST - 10 months ago

Annovis Achieves Significant Milestones and Sustains Strong Progress in Phase 3 Alzheimer's Program

2025-10-27T12:05:25.000Z - 10 months ago

Annovis Bio prices 1.67M shares at $2.05 in registered direct offering

Oct 27, 2025, 8:00 AM EDT - 10 months ago

Annovis Announces $3.4 Million Registered Direct Offering of Common Stock Priced At-the-Market under the NYSE Rules

Oct 15, 2025, 5:15 PM EDT - 11 months ago

Annovis Announces Closing of $6 Million Registered Direct Offering of Common Stock

2025-10-10T12:36:07.000Z - 11 months ago

Annovis Bio prices 4M shares at $1.50 in registered direct offering

Oct 10, 2025, 8:31 AM EDT - 11 months ago

Annovis Announces $6 Million Registered Direct Offering of Common Stock

Oct 9, 2025, 7:30 AM EDT - 11 months ago

Annovis Announces Novel Biomarker Data in Alzheimer's Patients Supporting Buntanetap's Potential as a Disease-Modifying Treatment

Sep 25, 2025, 7:30 AM EDT - 11 months ago

Annovis Appoints Mark Guerin as Chief Financial Officer

Sep 16, 2025, 7:30 AM EDT - 1 year ago

Annovis Reports Peer-Reviewed Publication Highlighting Pharmacokinetics of Novel Crystal Buntanetap

Sep 10, 2025, 12:00 PM EDT - 1 year ago

Annovis Bio Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 8:00 AM EDT - 1 year ago

Annovis to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 12, 2025, 4:05 PM EDT - 1 year ago

Annovis Provides Corporate Updates and Reports Second Quarter 2025 Financial Results

Aug 12, 2025, 12:00 AM EDT - 1 year ago

Annovis Bio Quarterly report: Q2 2025

Aug 12, 2025, 12:00 AM EDT - 1 year ago

Annovis Bio Earnings release: Q2 2025

Aug 7, 2025, 8:00 AM EDT - 1 year ago

Annovis Completes Full Patent Transfer to Crystal Buntanetap

Jun 26, 2025, 8:00 AM EDT - 1 year ago

Annovis to Attend the AAIC 2025 with Four Poster Presentations

Jun 24, 2025, 4:30 PM EDT - 1 year ago

Annovis Bio Transcript: Status Update

Jun 19, 2025, 6:30 AM EDT - 1 year ago

Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance

Jun 5, 2025, 8:00 AM EDT - 1 year ago

Annovis to Host Webinar and Live Q&A on June 24, 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results

May 13, 2025, 12:00 AM EDT - 1 year ago

Annovis Bio Earnings release: Q1 2025

May 13, 2025, 12:00 AM EDT - 1 year ago

Annovis Bio Quarterly report: Q1 2025

May 1, 2025, 8:00 AM EDT - 1 year ago

Annovis Bio Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Annovis Bio Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Annovis Bio Appoints Hui Liu as Director of Biostatistics

Mar 27, 2025, 4:30 PM EDT - 1 year ago

Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE

Mar 25, 2025, 8:00 AM EDT - 1 year ago

Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program

Mar 21, 2025, 5:05 PM EDT - 1 year ago

Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Mar 21, 2025, 12:00 AM EDT - 1 year ago

Annovis Bio Annual report: Q4 2024

Mar 21, 2025, 12:00 AM EDT - 1 year ago

Annovis Bio Earnings release: Q4 2024

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment

Feb 19, 2025, 8:30 AM EST - 1 year ago

Annovis to Host Patients' Live Forum on February 27, 2025

Feb 7, 2025, 8:00 AM EST - 1 year ago

Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Feb 5, 2025, 8:00 AM EST - 1 year ago

Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer's Disease

Feb 4, 2025, 4:31 PM EST - 1 year ago

Annovis Bio, Inc. Announces Closing of $21 Million Public Offering

Feb 3, 2025, 6:22 AM EST - 1 year ago

Annovis Bio, Inc. Announces Pricing of $21 Million Public Offering

Jan 31, 2025, 8:14 PM EST - 1 year ago

Annovis Bio, Inc. Announces Proposed Public Offering

ScottHopko Aug. 25 at 3:48 PM

$ANVS is brewing. $MRNA is up big today.

0 · Reply

FRF Aug. 25 at 3:06 PM

$ANVS

0 · Reply

NolAsrtormZ Aug. 25 at 2:33 PM

$ANVS institutions dont care how many shares Maria puts on the market 🤣 What if the offering is higher then current share value🤫🤫🤫

0 · Reply

NolAsrtormZ Aug. 25 at 2:23 PM

$ANVS they need zeeee, caszhh ;)

1 · Reply

NolAsrtormZ Aug. 25 at 2:03 PM

$ANVS Institutions could care less if Maria has to do another offering

1 · Reply

NolAsrtormZ Aug. 25 at 2:01 PM

$ANVS im gambling with the institutions at near, near All time Lows for a Phase 3 Alzheimers play

1 · Reply

NolAsrtormZ Aug. 25 at 2:00 PM

0 · Reply

To_De_Moon Aug. 25 at 1:32 PM

$ANVS https://zoom.us/webinar/register/WN_QRF6xO03S9GwsDvpfsxsog#/registration

0 · Reply

ForestFoxes Aug. 25 at 1:13 PM

$ANVS 📉 Corporate Update Webinar: Wednesday, September 2, 2026 at 4:00 pm EDT … followed by a live Q&A session with 900% confidence that the drug works.

1 · Reply

NolAsrtormZ Aug. 25 at 12:16 PM

$ANVS Gained at least 375 watchers that SAY NOTHING since full enrollment So a few of us keep them informed

2 · Reply

NolAsrtormZ Aug. 25 at 12:11 PM

$ANVS institutions thanking you

0 · Reply

NolAsrtormZ Aug. 25 at 12:09 PM

$ANVS Institutions are talking impatient retail shares. Rumors are institutions cant buy shares under $5.00 But seems they are buying hand fulls upon handfulls Just say millions of shares

2 · Reply

NolAsrtormZ Aug. 25 at 10:35 AM

$ANVS Currently trade under 100 million market cap

0 · Reply

NolAsrtormZ Aug. 25 at 10:35 AM

$ANVS Maria wants 20 BILLION for the company

1 · Reply

NolAsrtormZ Aug. 25 at 10:34 AM

$ANVS 2 examples of how much phase 3 data is worth At LEAST 10 BILLION

0 · Reply

NolAsrtormZ Aug. 25 at 10:33 AM

$ANVS All these new watchers must know Phase 3 Alzheimers data is worth AT LEAST 10 BILLION $$$$ SOOOOO, roughly $170 a share

0 · Reply

Veni_Vidi_Vici Aug. 24 at 1:14 PM

$ANVS I am no expert. Do your own due diligence. Understand the risks before investing in a clinical stage biotech. Annovis Followers on Stocktwits = 10,489

1 · Reply

WeAllFallDown Aug. 23 at 1:19 PM

$ANVS This is definitely worth a curious long position...risk and reward...let's see how our posts age...

1 · Reply

Biotechs5454 Aug. 22 at 2:13 PM

$ANVS Let’s see if anything of interest from the 9/2 call. Partnership or other non-dilutive financing would be fantastic.

3 · Reply

1ForTheMoney_ Aug. 21 at 3:40 PM

$ANVS It's really a blessing to have the stock price be so low for so long. The treatment is beneficial and safe. Buy the dips and enjoy the ride...

0 · Reply

Alex1710 Aug. 20 at 11:39 PM

$ANVS Year to date the IBB index is up almost 25% and tis POS is down 48%

1 · Reply

Alex1710 Aug. 20 at 8:16 PM

$ANVS All analyst data they have are post hoc data and not pre specified data so it makes them very poor on a statistical analysis. That's why any serious investors will invest.

0 · Reply

Market Cap	77.54M
Revenue (ttm)	0.00
Net Income (ttm)	-28.85M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	670,700
Avg Vol	752,378
Day's Range	N/A - N/A
Shares Out	42.61M
Stochastic %K	6%
Beta	1.25
Analysts	Strong Sell
Price Target	$10.75